{"id":"W2053960137","doi":"10.1158/1535-7163.targ-11-a50","title":"Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Pfizer (Canada); London Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Ontario Clinical Oncology Group; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"PTEN; Neuroblastoma RAS viral oncogene homolog; Medicine; Biomarker; Cancer; Genotyping; Exact test; Mutation; Internal medicine; Oncology; Genotype; Cancer research; KRAS; Gene; Biology; Genetics; Apoptosis; PI3K/AKT/mTOR pathway","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001372653,0.0009508038,0.001227371,0.0003438683,0.0002678942,0.0006690823,0.0004635288,0.0007709276,0.00421168],"category_scores_gemma":[0.0008713885,0.0003772786,0.0007826605,0.0003628399,0.0004114025,0.0004265247,0.0002143465,0.001572372,0.0009245767],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004836119,"about_ca_system_score_gemma":0.0007737387,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006127774,"about_ca_topic_score_gemma":0.001391654,"domain_scores_codex":[0.9996564,0.0001444205,0.00002742977,0.00007012811,0.00004871052,0.00005286363],"domain_scores_gemma":[0.9994636,0.0000990165,0.00006570363,0.00003824798,0.00005438416,0.0002791718],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6546128,0.03051248,0.02940537,0.001048937,0.002989082,0.0006961365,0.0001940497,0.002411158,0.173874,0.0001973773,0.00861937,0.09543924],"study_design_scores_gemma":[0.3407111,0.5443403,0.07708984,0.00005996319,0.002244903,0.001041823,0.00005879392,0.003112507,0.02623515,0.0002367884,0.004810002,0.00005884632],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910117,0.002352001,0.000629251,0.0003531874,0.000113168,0.001421596,0.001990462,0.00008408697,0.002044528],"genre_scores_gemma":[0.9894543,0.0009352203,0.001515914,0.0006260183,0.0001075039,0.0009972909,0.003790705,0.00002885487,0.002544182],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00421168,"threshold_uncertainty_score":0.01408952,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06901843089128866,"score_gpt":0.3468851743945893,"score_spread":0.2778667435033007,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}